Posted by Michael Wonder on 24 Aug 2023
Alentis Therapeutics receives FDA fast track designation for ALE.C04 for the treatment of Claudin-1 positive HNSCC
24 August 2023 - Fast Track designation accelerates the path to US submission for the investigational monoclonal antibody in patients with recurrent or metastatic CLDN1 positive HNSCC.
Alentis Therapeutics announced today that the US FDA has granted fast track development program for ALE.C04 for the treatment of patients with recurrent or metastatic, CLDN1 positive HNSCC.
